Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: al who wrote (8046)	5/13/1998 4:35:00 PM
From: j bayer	Respond to of 23519

There was an article on the front page of our local newspaper yesterday whereby the American College of Obstetricians and Gyn is accusing insurers of gender bias. The group states "Pregnancy is a medical condition, just like impotence. And the cost benefit of preventing pregnancy is much greater than treating impotence." ACOG is taking offense that insureres are covering impotence drugs and NOT birth control pills. Interesting point IMO. The article went on to say "Americans are split over whether health plans should cover Viagra. In a new USA Today poll, 59% called the drug a good thing for society as a whole but 50% said health plans should not pay for it" Should pressure be placed on insurers to NOT cover impotent drugs, it will have an affect on all ED companies IMO. Sorry if this article was already mentioned on this thread, haven't had the time to go thru each post for a few days but wanted to bring the article to everyone's attn. Good luck to all.

To: al who wrote (8046)	5/13/1998 8:05:00 PM
From: DaiS	Respond to of 23519

al I found it interesting to plot out and compare the muse and caverject numbers since viagra introduction. Caverject repeats essentially not affected; smallish new cripts decline now levelling. Muse repeats somewhat more strongly affected but levelling; muse new scripts massive decline with some indications of levelling during last two weeks (otherwise they'll go through the floor). I think the picture is similar if the changes are represented as % of initial sales. So muse scripts are lost at a greater rate to the viagra ocean than caverject scripts particularly the new scripts. What does this mean? Many muse users new to ED treatment and more likely to change than long term caverject users satisfied with their technique? Caverject users have more serious ED than muse users and more likely to be told not bother changing to viagra? It might be interesting to look at muse/caverject figures before viagra introduced. DaiS